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Abstract
The use of cardiac biomarkers in the intensive care setting is
gaining increasing popularity. There are several reasons for this
increase: there is now the facility for point-of-care biomarker
measurement providing a rapid diagnosis; biomarkers can be used
as prognostic tools; biomarkers can be used to guide therapy; and,
compared with other methods such as echocardiography, the
assays are easier and much more affordable. Two important
characteristics of the ideal biomarker are disease specificity and a
linear relationship between the serum concentration and disease
severity. These characteristics are not present, however, in the
majority of biomarkers for cardiac dysfunction currently available.
Those clinically useful cardiac biomarkers, which naturally received
the most attention, such as troponins and B-type natriuretic
peptide, are not as specific as was originally thought. In the
intensive care setting, it is important for the user to understand the
degree of specificity of these biomarkers and that the interpretation
of the results should always be guided by other clinical information.
The present review summarizes the available biomarkers for
different cardiac conditions. Potential biomarkers under evaluation
are also briefly discussed.
Introduction
Nearly 30% of patients admitted to a general intensive care
unit (ICU) have underlying cardiac diseases, and approxi-
mately one-half of these 30% are admitted to the ICU with
cardiac problems as the primary cause [1,2]. The latter group
is mainly comprised of patients with acute myocardial infarc-
tion, acute heart failure (HF) or cardiogenic shock. Pulmonary
embolism, sepsis-related cardiac dysfunction and arrhythmias
are also commonly found in the ICU.
The diagnosis of cardiac problem can be a difficult task in the
ICU, partly due to the nonspecificity of clinical signs and
symptoms. Prompt treatment can reduce mortality and
improve patient outcome, and therefore the value of rapidly
identifying the problem and assessment of the condition
cannot be understated. Although the introduction of intensive
care echocardiography has made the diagnoses easier,
diagnoses based on echocardiography alone are not always
sufficient and the application requires ready availability of
skilled operators [3]. For example, while an enlarged right
ventricle denotes pressure or volume overloading, echo-
cardiography sheds little light on the etiology. Proper diagnosis
requires the incorporation of various clinical information
including medical history, physical examination, electro-
cardiography, chest X-ray scans and, recently, biomarker levels.
Biomarkers offer certain advantages over other diagnostic
tools. First, biomarkers can help clinicians efficiently formulate
differential diagnoses. Second, as biomarker levels often
correlate with the severity of the disease, they can be used to
guide therapy. Third, some of the biomarkers can provide
prognostic values. The earliest type of cardiac biomarkers
was cardiac enzymes, the uses of which were restricted to
the diagnosis of acute myocardial infarction (cardiac
necrosis). The discovery of new cardiac biomarkers and the
increased sensitivity of the assays have extended the
boundary of applications, for example, to the detection of
other cardiac pathophysiological processes such as pump
failure and right ventricular pressure overload secondary to
pulmonary emboli. The present review summarizes the
findings of some cardiac biomarkers and examines their
usefulness in the ICU.
Detection of cardiac dysfunction in the ICU
Traditionally, the intensivist has relied on medical history,
physical examination and basic investigations such as the
electrocardiogram and the chest X-ray scan to detect cardiac
dysfunction. Occasionally, invasive measurements such as
the pulmonary artery catheter will be employed. Although
echocardiography can play a major role, the limited availability
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in many ICUs prompts the need for a simpler method to
detect cardiac dysfunction. Serum biomarkers seem able to
fulfill this role, and some have been evaluated for uses in
myocardial ischemia and necrosis, acute decompensating
HF, reversible myocardial depression, valvular disease and
pulmonary embolus.
Acute heart failure
Nearly 5 million people in the United States and at least 10
million people in Europe have HF. In the United States, HF
accounted for at least 20% of all hospital admissions for
patients over 65 years old [4]. From 1989 to 2003,
approximately 14,000 patients were diagnosed with HF in
New South Wales, Australia each year [5].
B-type natriuretic peptide
B-type natriuretic peptide (BNP) is a 32-amino-acid peptide
secreted mainly by the cardiac ventricles in response to
pressure or volume overloading (ventricular stretch) [6]. BNP
causes diuresis and natriuresis by decreasing tubular salt and
water reuptake, increasing the glomerular filtration rate and
inhibiting angiotensin action on the proximal tubule [7]. BNP
also induces vasodilatation, thereby reducing afterload [8].
The peptide therefore plays an important role in the
maintenance of circulatory homeostasis and serves to protect
the cardiovascular system from volume overload. BNP has
been used to differentiate cardiac causes of dyspnea from
pulmonary causes in the emergency setting [9].
A number of clinical and epidemiology studies have demon-
strated the relationship between HF and BNP or N-terminal-
proBNP [10-12]. BNP is now commonly used to assist the
diagnosis of HF, and has been endorsed as a useful
diagnostic marker for HF [13,14]. In the Breathing Not Properly
study, a plasma BNP level >100 pg/ml was demonstrated to
predict congestive HF (sensitivity = 90%, specificity = 73%)
[15]. BNP fails to correlate with the New York Heart
Association class of dyspnea, however, and does not predict
the severity of HF [16]. BNP is elevated in a number of
conditions and is not specific to heart failure (Table 1).
Considering the consistent high negative predictive values,
BNP is most useful as a rule-out tool clinically.
In the ICU, plasma BNP concentrations are increased in
patients with different types of cardiac dysfunction, including
heart failure, left ventricular diastolic dysfunction, right
ventricular pressure overload, and valvular stenosis. A BNP
level >144 pg/ml predicts cardiac dysfunction with high
sensitivity (92%) and high specificity (86%) [2]. As BNP is
increased in a variety of cardiac conditions, it offers little help
in differential diagnosis and has low specificity for detecting
specific cardiac disease such as heart failure [2]. BNP levels
are also found to be significantly confounded by age, gender
and fluid loading [1,17,18]. Owing to its high negative
predictive value, BNP is best used for ruling out cardiac
dysfunction. Since BNP is increased in various cardiac
conditions, the use of BNP as a specific diagnostic tool for
HF cannot be recommended in the ICU.
Troponins
Although cardiac troponins (cTn) were initially used as serum
markers for myocardial infarction, it is now known that cTn
were also elevated in patients with HF even in the absence of
overt ischemia [19,20]. The percentage of HF patients with
elevated cTn could be as high as 45% [21]. The mechanism
for this elevation is believed to be due to ongoing myocyte
injury and the progressive loss of cardiac myocytes, hence
releasing cTn into the circulation [22,23].
As a diagnostic tool for HF, however, cTn lack both sensitivity
and specificity. cTn are more useful as a prognostic tool.
Increased serum cTn, either cardiac troponin I (cTnI) or
cardiac troponin T (cTnT), in patients with HF have been
demonstrated to be associated with increased risks of
cardiac events, rehospitalization and mortality [19,21,24,25].
Other potential heart failure markers
IL-18 is a member of the IL-1 family and possesses pro-
inflammatory functions. IL-18 induces TNFα and IL-6. Circu-
lating IL-18 is markedly increased in patient with congestive
HF, and is decreased with inotropic treatment [26,27]. As
plasma IL-18 levels decrease with improving clinical status,
IL-18 can be used as a surrogate for guided therapy [27].
Noteworthy, however, is the fact that IL-18 is also elevated in
ischemic heart disease [28].
Carbohydrate antigen 125 was originally used as a tumor
marker but was later also found to be increased in patients
Table 1
Conditions or factors commonly associated with B-type
natriuretic peptide or N-terminal-pro-B-type natriuretic peptide
elevations
Age
Arrhythmias
Cardiomyopathy: hypertrophic, ischemic, or dilated
Congestive heart failure
Coronary artery disease
Gender
Hypertension
Left ventricular diastolic dysfunction
Pulmonary embolism
Renal failure
Right heart failure
Right ventricular overloading: fluid, or pressure overloading
Sepsis or septic shock
Sepsis-related myocardial dysfunctionPage 3 of 9
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with HF [29,30]. Serum carbohydrate antigen 125 correlates
with clinical status (New York Heart Association class), and
correlates weakly with right atrial pressure, right ventricular
systolic pressure and pulmonary artery wedge pressure
[31,32]. Interestingly, carbohydrate antigen 125 does not
seem to correlate with most of the echocardiographic left
ventricular systolic and diastolic function parameters [31,32].
The fact that carbohydrate antigen 125 is also increased in
isolated right heart failure, pericardial effusion and renal
dysfunction precludes its use as a diagnostic tool for HF
[33,34], although its significant reduction with aggressive
treatment may render it a surrogate marker [31].
Cardiac injury and necrosis
Creatine kinase-myocardial band
Irreversible myocardial necrosis is the landmark of acute
myocardial infarction. Myocardial injury leads to the release of
specific cytosolic substances that can be used as a marker
for injury. Creatine kinase-myocardial band (CK-MB) is an
enzyme present primarily in cardiac muscles [35]. The
enzyme is released rapidly (within 4 to 6 hours) into the
circulation after the onset of infarction. It peaks at 24 hours,
and returns to normal levels by 36 to 72 hours [36]. CK-MB
is not cardiospecific, however, and skeletal muscle injury can
increase its circulatory level [37]. Other uses of CK-MB
include estimating the infarct time, the infarct size and
expansion, and reinfarction [38].
Troponins
Troponin T and troponin I are part of the contractile apparatus
of striated muscle, including the cardiac myocytes. cTnT and
cTnI are the most specific and sensitive markers of myocardial
injury, and there is no clinical difference between cTnT and
cTnI for diagnosing cardiac necrosis [39]. The trigger for cTn
release is necrosis, and cTn assays can detect as little as 1 g
myocardial necrosis [40]. cTn begin to increase within 2 to
4 hours after onset of symptoms, and remain elevated for
days. Early release is believed to be attributable to the
cytosolic pool, and later release attributable to the structural
pool. cTn are particularly useful in determining whether a given
event is acute, chronic or reinfarction by observing if the level
is increasing or re-elevating.
Not only are cTn elevated in patients with acute and chronic
cardiovascular disease, but also in patients with non-
cardiovascular disease. Studies in both symptomatic and
asymptomatic patients have shown that renal failure is
associated with chronic elevations of cTn [41]. Sepsis or
pulmonary embolism can also independently increase cTn
[42]. Other causes of cTn elevation include trauma,
pericarditis, HF, hypertension, and inflammatory diseases
(Table 2) [43]. Encountering patients with elevated cTn
without apparent causes is also not infrequent. There are a
number of reasons for this, including the high sensitivities of
the new-generation assays, the use of low cutoff points and
the imprecision of the assays. In view of this uncertainty,
serial testing has been recommended to improve specificity
[44]. A single measurement of cTn, albeit elevated, does not
reflect the mechanism of myocardial damage and should not
be used alone to diagnose myocardial infarction. cTn,
however, is still useful in predicting outcomes in patients with
or without acute coronary syndromes [45,46].
Heart-type fatty acid binding protein
Heart-type fatty acid binding protein (H-FABP) is a small
cytosolic protein found in cardiomyocytes responsible for
fatty acid transportation [47]. H-FABP is rapidly released into
the circulation following myocardial injury, and is detectable
within 2 to 3 hours of the onset of clinical symptoms [48].
The diagnostic sensitivity of H-FABP for acute myocardial
infarction in the superacute phase (within the first 3 hours) is
93.1%, which is higher than that for CK-MB and for cTn. The
specificity, however, is lower than that of cTn (64.3%) [49].
In a study involving 108 patients with acute ischemic-type
chest pain admitted to a mobile intensive care unit, H-FABP
showed a better sensitivity to identify myocardial infarction
than cTnI, myoglobin and CK-MB. In patients with normal
prehospital cTnI levels and no ST-elevation (n = 63), a
positive H-FABP test had 83.3% sensitivity and 93.3%
specificity for predicting evolving myocardial infarction [50].
H-FABP also offers better sensitivity than cTnT for detecting
ongoing myocardial damage in congestive HF [51]. Elevated
serum H-FABP is associated with an increased risk of death
and major cardiac events in patients with acute coronary
syndromes despite negative serum cTn and BNP [52].
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Table 2
Conditions commonly associated with cardiac troponin
elevations
Arrhythmias
Congestive heart failure
Coronary artery disease
Coronary vasospasm
Critically ill patient
Hypertension
Myocarditis
Pericarditis, acute
Pulmonary embolism
Pulmonary hypertension, severe
Renal failure
Sepsis/septic shock
Sepsis-related myocardial dysfunction
Systemic inflammatory diseases
Takotsubo cardiomyopathy
TraumaInflammatory markers of atherosclerotic plaque
Inflammation plays a key role in coronary artery disease [53].
All stages of plaque development and eventual rupture
leading to acute coronary syndromes can be considered an
inflammatory response [54]. The detection of key molecules
involved in the atherosclerotic inflammatory cascade there-
fore offers an attractive approach for detecting cardiac
ischemia and predicting outcomes [55].
C-reactive protein
C-reactive protein (CRP) is produced mainly in the liver and is
believed to have a direct role in the pathophysiology of
atherosclerosis. CRP enhances macrophage uptake of low-
density lipoprotein and contributes to foam cell formation.
The protein also causes plaque instability, induces adhesion
molecule expression, and associates with endothelial dys-
function [56,57]. CRP was elevated in patients with unstable
angina but not in those with variant angina caused by
vasospasm, indicating that CRP is associated with inflam-
mation in the coronary artery rather than in the ischemic
myocardium [58]. CRP was also increased in other inflam-
matory conditions such as acute injury, infection, and chronic
renal failure [59,60]. High levels of CRP in unstable angina
are associated with worsening outcome [61].
Interleukins
IL-6, a proinflammatory cytokine produced by macrophages in
atherosclerotic plaque, induces hepatic synthesis of all the
acute phase proteins, including CRP [54,62]. Elevated IL-6
was associated with a 3.5-fold increase in 1-year mortality in
patients with acute coronary syndrome [63]. Healthy
individuals with high IL-6 also had an increased risk for future
myocardial infarction [64]. One should bear in mind, however,
that IL-6 is unlikely to be helpful in differentiating diseases
because it is an inflammatory cytokine that is elevated in
many diseases, and in almost any inflammatory disease. As
such, IL-6 is not specific enough to be used as a diagnostic
tool.
IL-18 is also a proinflammatory cytokine that is highly
expressed in atherosclerotic plaque (macrophages). Signifi-
cantly higher levels of IL-18 mRNA were found in sympto-
matic (unstable) plaque than in asymptomatic (stable) plaque,
suggesting IL-18 destabilizes atherosclerotic plaque leading
to ischemic syndromes [65,66]. IL-18 was a strong predictor
of death from cardiovascular causes in patients with coronary
artery disease [67]. Owing to its high level in HF, IL-18 is not
suitable for selectively diagnosing ischemic heart disease.
Sepsis-related myocardial dysfunction
Sepsis-related myocardial dysfunction (SRMD) refers to the
transient depression in left ventricular function in patients with
sepsis [68]. SRMD is a common complication, occurring in
up to 50% of septic patients, and early recognition and
aggressive supportive therapy are mandatory as the mortality
in these patients is high [69].
B-type natriuretic peptide
Patients with severe sepsis or septic shock had elevated
BNP levels [1,2,70]. BNP correlated with the cardiac index in
patients with septic shock, and levels were higher in those
with reduced left ventricular function [71,72]. Our recent
study found that patients with severe sepsis or septic shock
had higher BNP than normal levels regardless of cardiac
function. Interestingly, differentiation of septic patients with or
without SRMD with BNP alone was proved not practical as
both populations demonstrated similar levels of BNP [73].
Given the number of confounding factors of BNP in this
setting, the specific use of BNP in diagnosing SRMD is not
recommended at this stage [2,74].
Cardiac troponins
cTn levels have been shown to be associated with SRMD
[75,76]. Neither myocardial ischemia nor necrosis (irrever-
sible damage) could fully explain the elevated cTn levels
observed in SRMD [77]. It is postulated that a transient
(reversible) increase in membrane permeability of the cardio-
myocytes in SRMD, together with intracellular degradation of
troponin I, was responsible for the increased cTn levels
[78,79]. The use of cTn as a diagnostic tool for SRMD is
again limited by its low specificity.
Pulmonary embolism
cTn and BNP were elevated in patients with pulmonary
embolism, and could be the result of right ventricular overload
or dysfunction secondary to pulmonary hypertension [80,81].
About 70% of patients with pulmonary embolism had
elevated cTnI, and was significantly associated with right
ventricular dysfunction [80]. BNP and N-terminal-proBNP
were also found to be elevated in pulmonary embolism, but
only in patients with concomitant right ventricular dysfunction
[82]. BNP concentrations were found proportional to the
severity of embolism, probably due to the increasing degree
of right ventricular stress [83].
In a recent single-centered small study, it was observed that
patients with elevated H-FABP on admission had a higher risk
of developing major pulmonary embolism-related complica-
tions [84]. H-FABP was also found to have a better
discriminatory ability for pulmonary embolism-related com-
plications than cTnT and N-terminal-proBNP [84].
Other potential cardiac biomarkers
Ischemia-modified albumin
The ability of human serum albumin to bind cobalt is reduced
in myocardial ischemia [85,86]. Using blood samples collec-
ted within 2 hours of arrival at the Emergency Department,
ischemia-modified albumin (noncobalt-binding albumin) was
found to be increased in patients with unstable angina
(sensitivity = 91%) [87]. The sensitivities, however, were
lower for detecting myocardial infarction. Muscle ischemia,
low albumin levels and physical exercise have all been shown
to affect ischemia-modified albumin levels [88-90].
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Choline is released by cleavage of membrane phospholipids
by phospholipase D. Whole blood choline and plasma choline
concentrations increase rapidly after activation of phos-
pholipase D in acute coronary syndromes [91]. Whole blood
choline and plasma choline are significant and independent
predictors of major cardiac events in admission cTnT-negative
patients [92]. Both cholines are predictive for events related to
tissue ischemia, and are independent of other known factors
such as age, gender, prior myocardial infarction, coronary risk
factors and the electrocardiogram [92].
CD154
The soluble CD40 ligand, now known as CD154, is found
both on the cell surface and in soluble form. CD154 is a
platelet-derived inflammatory cytokine and can be found on
lymphocytes and the endothelial surface. Interaction with the
CD40 receptor leads to B-cell activation and induction of
other inflammatory markers, such as cell adhesion molecules,
cytokines and chemokines [93]. In patients with HF, the
abundance of CD154 on platelets is increased and
correlates with New York Heart Association classification
[94]. Elevated CD154 levels independently predict cardio-
vascular events and death [95].
Urocortin
Urocortin, like BNP, is a cardioprotective peptide and can be
found in the brain and in the heart [96]. Urocortin increases
myocardial contractility, induces vasodilatation, and possesses
antiapoptotic and anti-inflammatory activities [97,98]. In
patients with HF, urocortin is associated with left ventricular
dysfunction [99]. Studies involving humans are limited, and
more research is needed before urocortin can be used as a
biomarker.
Myeloperoxidase
Myeloperoxidase, a proinflammatory enzyme involved in low-
density lipoprotein oxidation, is significantly elevated in HF
patients [100]. Elevated plasma myeloperoxidase levels in HF
subjects were associated with worsening conditions [101]. In
the emergency setting, myeloperoxidase predicts the risk of
myocardial infarction in patients with chest pain even in the
absence of cardiac necrosis [102].
Multimarker approach
The reliance on a single biomarker for diagnostic or prognostic
purpose has in many cases proven unsatisfactory. A number
of studies have demonstrated that the value of using
biomarkers for diagnosis or prognosis could be more apparent
if several biomarkers were used together. For example, when
CRP was used in conjunction with BNP or cTn in the
emergency and cardiology settings, the prognostic value was
better than each biomarker used singly [103,104]. Similarly,
the combination of cTnT, electrocardiogram and ischemia-
modified albumin could identify 95% of patients whose chest
pain was attributable to ischemic heart disease [87,105].
Intensive care unit
A number of cardiac biomarkers are now commonly used in
the ICU; in particular, cTn, CRP, and CK-MB. cTn are known
to be increased in intensive care patients, and are not
confined to patients with cardiac injury or acute coronary
syndromes [106-109]. Nonthrombotic cardiac conditions, as
well as noncardiac conditions, are also associated with
increased cTn levels (Table 2). The presence of elevated cTn
per se is not sufficient to diagnose cardiac injury [110,111].
Based on the data provided by Lim and colleagues [111], the
Bayesian probability that a critically ill patient with an
increased troponin level will have cardiac injury (myocardial
infarction) is between 0.5 and 0.6; that is, the chance of
prediction is only slightly better than tossing a coin.
Although CRP has been used as a cardiac marker in the
emergency or cardiology settings, it is not normally used as a
cardiac biomarker in the ICU. CRP is instead used as an acute
phase inflammatory marker to assist the diagnosis of infection
[112,113]. In a heterogeneous ICU population, elevated
concentrations of serum CRP on ICU admission were
correlated with an increased risk of organ failure and death
[114]. To date, we are not aware of any study demonstrating
the usefulness of CRP as a cardiac biomarker in the intensive
care setting.
BNP is also a promising biomarker for use in the ICU, but its
application is confined mainly to screening purposes. Appli-
cations in the area of differential diagnosis, guiding treatment
as well as prognosis are still developing.
Given the comorbidities, aggressive treatments and the lack
of specificity and sensitivity of a single cardiac marker, it is
probable that the intensive care setting will benefit from the
multimarker approach. The development of a multimarker
approach for ICU use, however, should be distinctive; the
question of which biomarkers are the best to use will require
further research.
Conclusion
There is no doubt that cardiac biomarkers play an important
role in providing additional information for differential
diagnosis in the ICU. This additional information, depending
on the biomarker(s) used, may include the presence or
absence of cardiac disease, cardiac injury, atherosclerotic
plaque, or pulmonary embolism (Fig. 1). While most
information could be obtained from detailed clinical
investigations, such as echocardiography, angiography and
other hemodynamic assessments, the biomarker approach
provides quick information and adds value to the diagnostic
process. The helpfulness of the biomarker information will
depend on the way in which it is used (for example, sampling
time, the cutoff points chosen), the clinician’s belief and
approach, as well as the clinical context. The main attractions
of using biomarkers are the close link between the
Available online http://ccforum.com/content/12/3/215
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the biomarkers, the correlation between the biomarkers and
the severity of the disease, the provision of prognosis, and
the ease of performing the test.
The use of cardiac biomarkers in the ICU continues to evolve
with new findings. Ideally, the biomarkers should be specific
for cardiac diseases, but this is both theoretically and
practically impossible due to the sharing of common
biochemical or immunological pathways of the pathophysio-
logical processes. Despite most of the biomarkers lacking
sensitivity and specificity, this should not prevent biomarkers
being used in a clinically useful way. Clinicians need to be
aware of the biomarkers’ limitations, and should interpret
them within the clinical context. A multimarker approach may
prove a valuable approach in the future for the ICU.
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